Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

About this update from Ernexa Therapeutics Inc.

New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability Inaugural video highlights Company's mission to provide hope, scientific strategy and commitment to advancing differentiated cell therapies Access the Ernexa CEO Corner here CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today launched its CEO Corner platform featuring Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. The CEO Corner platform is intended to provide additional perspective on company developments, scientific progress, strategic priorities and the Company's mission to advance innovative therapies for patients facing serious disease. The platform is designed to provide stakeholders with insights beyond traditional corporate announcements, offering additional context around Ernexa's strategy, development programs, scientific approach and long-term vision. "CEO Corner gives us an opportunity to connect directly with shareholders and provide a deeper look into the science, strategy and vision driving Ernexa forward," said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. "We believe innovation only matters if it ultimately reaches patients. Our goal is to develop therapies that not only address significant unmet needs, but also have the potential to improve accessibility, affordability and outcomes for patients facing serious disease. Through CEO Corner, I look forward to sharing our progress, the hope we aim to deliver to patients and families and the opportunities we see ahead." The inaugural CEO Corner segment highlights Ernexa's mission, scientific strategy and commitment to advancing differentiated cell therapies designed to deliver hope for patients facing significant unmet medical needs. The discussion also highlights the Company's focus on engineered, off the shelf cell therapy platforms and their potential to improve manufacturing scalability, consistency and broader patient accessibility. The Ernexa CEO Corner is now accessible on the Company's website and social media channels. Access it here . For more information about ERNA-101 and the Company's development plans, visit www.ernexatx.com About Ernexa Therapeutics Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

View stock analysis, news, and events for Ernexa Therapeutics Inc.